jump to navigation

Lisa Warren Examines the Value of In-Person Interviews for Expediting Patent Allowance in Mass. Lawyers Weekly Article 08/15/2017

Posted by Morse Barnes-Brown Pendleton in Attorney News, Intellectual Property, Life Sciences.
Tags: , , , ,
add a comment

LMW Headshot Photo 2015 (M0846622xB1386)In her Massachusetts Lawyers Weekly article “Expediting Patent Allowance with In-Person Interviews,” patent attorney Lisa Warren explains why it may be beneficial to take advantage of in-person interviews with the U.S. Patent & Trademark Office in order to expedite the allowance of a patent. Although options such as telephone or video conference interviews may be available and more convenient, Lisa notes:

sometimes there is simply no substitute for direct interpersonal interaction with an examiner to build rapport and improve the mutual understanding of the issues.”

Additionally, Lisa addresses relevant considerations when deciding if in-person interviews are preferable during the patent application process, as well as requirements for the interview itself. These and other insights from Lisa can be found in the full article.

Lisa McKerracher of BioAxone BioSciences Joins Advisory Panel for Christopher Reeve Foundation 08/10/2017

Posted by Morse Barnes-Brown Pendleton in Client News, Life Sciences.
Tags: , , ,
add a comment

Lisa McKerracher, CEO of MBBP client BioAxone BioSciences, has accepted the role of Consortium Advisory Panelist for the Christopher & Dana Reeve Foundation. Dr. McKerracher will “direct the foundation’s focus toward the identification, development, and translation of potential Spinal Cord Injury (SCI) therapies into the clinic.”

BioAxone BioSciences is a clinical-state biopharmaceutical company developing regenerative therapeutic drugs based on a deep understanding of axon regeneration and neuronal signaling pathways. The Christopher & Dana Reeve Foundation is dedicated to advancing quality of life and discovering cures for spinal cord injury.

More information can be found in the full release.

David Sabatini To Be Awarded 2017 Dickson Prize in Medicine 08/10/2017

Posted by Morse Barnes-Brown Pendleton in Client News, Life Sciences.
Tags: , , ,
add a comment

whitehead-institute-client-logo-sm-m0055040xb1386Biologist David Sabatini of MBBP client Whitehead Institute will receive the University of Pittsburgh’s 2017 Dickson Prize in Medicine. The Dickson Prize in Medicine is awarded annually to a leading American investigator who is engaged in innovative, paradigm-shifting biomedical research.

Sabatini discovered mTOR, a key cellular regulatory metabolic pathway. In addition to being a member of the Whitehead Institute for Biomedical Research, he teaches biology at MIT and is a senior associate at the Broad Institute of MIT and Harvard University. He is also a member of the MIT Koch Institute for Integrative Cancer Research and is a Howard Hughes Medical Institute investigator.

The award will be presented to Sabatini in October at the University of Pittsburgh’s Science 2017 event. More information can be found on the University’s Dickson Prize in Medicine page.

Bach Pharma’s GVT Drug Reverses Brain Dysfunction, Report Shows 08/09/2017

Posted by Morse Barnes-Brown Pendleton in Client News, Life Sciences.
Tags: , , , ,
add a comment

Firm client Bach Pharma’s GVT drug successfully reverses brain dysfunction and therefore may be an effective treatment for victims of Gulf War Illness (GWI), according to a Department of Defense report on the results of a multi-year pre-clinical study conducted by Ashok K. Shetty, PhD, Associate Director and Professor at the Institute for Regenerative Medicine at the College of Medicine at Texas A&M University System. GWI is prevalent among servicemen and women from the Gulf War and can cause memory impairment, depression, and anxiety. The study was conducted under a grant from the DoD.

GVT has proven both neuro-protective and neuro-generative and could potentially act as a therapeutic treatment for chemical poisoning associated disorders. The fact that GVT regenerates stem cells and neurons was an unexpected finding of this study. Based on these results, Dr. Shetty has established a collaboration with Dena Davidson, PhD, deputy director of research at the Veterans Integrated Service Network (VISN) 17 Center of Excellence for Research on Returning War Veterans to pursue clinical trials in GWI patients.

Congratulations to our client, Bach Pharma, on this extraordinary achievement. Read the full press release for more information.

Mike Jabbawy Participating on Shoobx Startup Panel 08/08/2017

Posted by Morse Barnes-Brown Pendleton in Attorney News, Corporate, Events, Venture Capital & Private Equity.
Tags: , , ,
add a comment

MRJ Headshot Photo 2017 (M1047116xB1386)On September 26, corporate partner Mike Jabbawy will take part in the panel “How to Start a Startup”. The panel is part of Shoobx’s Startup Series, which features real life stories from startup founders, investors, and community members. Items of discussion will include choosing a form of entity for a business, choosing co-founders, and how to find assistance to get your business off the ground.

For more information, including registration details, visit our VCs and Startups blog.

NIH/SBIR Grant Awarded to Firm Client BioAxone BioSciences for BA-1049 Inhibitor Research 08/03/2017

Posted by Morse Barnes-Brown Pendleton in Client News, Life Sciences.
Tags: , ,
add a comment

The National Institutes of Health (NIH), Small Business Innovation Research (SBIR), and National Institute of Neurological Disorders and Stroke have awarded firm client BioAxone BioSciences, Inc. with a $1.5 million grant. The grant is for continued research for BioAxone’s Rho Kinase 2 (ROCK2) inhibitor, BA-1049, a transformative drug to treat cerebral cavernous malformation, a serious genetic disease.

BioAxone is a clinical-state biopharmaceutical company developing regenerative therapeutic drugs based on a deep understanding of axon regeneration and neuronal signaling pathways.

Congratulations to our client on receiving the grant and on their revolutionary drug research. For more information, read the full release.

Scott Connolly Comments on the Importance of Properly Classifying Workers in Accounting Today 08/03/2017

Posted by Morse Barnes-Brown Pendleton in Attorney News, Employment.
Tags: , , , , ,
add a comment

M0846523In Accounting Today’s article “Properly Classifying Workers Remains a Major Problem“, employment attorney Scott Connolly comments on how worker misclassification is a prevalent issues for both the Internal Revenue Service and state taxing officials. Companies that misclassify employees as independent contractors avoid paying numerous payments under the Federal Family and Medical Leave Act, which can lead to trouble with the IRS or with the misclassified employee.

For more information, visit our Massachusetts Employment Law Blog.

Firm Clients Sheprd and iZotope Are Finalists in MassTLC Leadership Awards 07/27/2017

Posted by Morse Barnes-Brown Pendleton in Client News, Computer Software & Hardware, Internet and E-Commerce, Telecommunications & Networking.
Tags: , , ,
add a comment

Firm clients Sheprd and iZotope are among the 2017 MassTLC Technology Leadership Awards finalists. The awards, presented by the Mass Technology Leadership Council, are comprised of individual and company categories, including CEO of the Year, Emerging Executive of the Year, Emerging Company of the Year, Cutting Edge Technology of the Year, and Technology for a Better Tomorrow, among others.

Sheprd and iZotope are both finalists in the Innovative Tech of the Year: Consumer category. The winners will be announced at the MassTLC Leadership Awards Gala on September 14th.

Congratulations and good luck to our clients, Sheprd and iZotope.

Scott Bleier Moderating ABA Venture Capital Webinar This Thursday 07/24/2017

Posted by Morse Barnes-Brown Pendleton in Attorney News, Corporate, Events, Venture Capital & Private Equity.
Tags: , , ,
add a comment

M0846500This Thursday, July 27th, beginning at 1pm EST, corporate attorney Scott Bleier will moderate the ABA Business Law Section webinar “Roadmap of a Venture Capital Deal“. The panel will cover various topics of the lifecycle of a venture capital financing transaction.

Visit our VCs and Startups blog for more information about the webinar and details on how to register.

BioAxone BioSciences Peer-Reviewed Research Article Published in Frontiers Journal Series 07/20/2017

Posted by Morse Barnes-Brown Pendleton in Client News, Life Sciences.
Tags: , ,
add a comment

Firm client BioAxone BioSciences announced that its peer-reviewed research article on axon regeneration was published in Frontiers Journal Series, Frontiers in Molecular Neuroscience. The article “MAG, Myelin and Overcoming Growth Inhibition in the CNS” was written by BioAxone’s CEO Lisa McKerracher, Ph.D. and Kenneth Rosen, Ph.D., VP of Research. Frontiers in Molecular Neuroscience publishes rigorously peer-reviewed research that aims to identify key molecules underlying the structure, design, and function of the brain across all levels.

BioAxone is a clinical-state biopharmaceutical company developing regenerative therapeutic drugs based on a deep understanding of axon regeneration and neuronal signaling pathways.

Congratulations to our client on this achievement. For more information, read the press release.

MBBP Publishes July M&A Today Newsletter 07/13/2017

Posted by Morse Barnes-Brown Pendleton in M&A, MBBP news.
Tags: , , , ,
add a comment

2016-08-08_16-11-25The latest edition of our M&A Today Newsletter is published!

Articles include:

Plus a special attorney profile of corporate partner Joe Marrow on page four.

Find more information view our M&A blog or read the full newsletter.

Corporate Attorney Shannon Zollo Explains In-House Counsel’s Role in Due Diligence 07/05/2017

Posted by Morse Barnes-Brown Pendleton in Attorney News, Corporate, Intellectual Property.
Tags: , , , ,
add a comment

M0846567In Corporate Counsel’s article “10 Uber In-House Attorneys Saw Due Diligence Report in Battle With Alphabet“, Shannon Zollo comments on the role of in-house counsel in the due diligence process. The article discusses a due diligence report from Uber’s acquisition of Otto, in which Alphabet claims there is proof that Uber knowingly acquired stolen intellectual property. As such, the importance of the due diligence process is highlighted and, in particular, in-house counsel’s role in the process.

Shannon explains that the goal of the due diligence period is to review a target company in a merger or acquisition and ascertain whether or not there are any potential issues. He notes:

The purpose of a diligence report is to understand as best as is possible before you close, the nature of the target and whether that target fits within your acquisition profile across the board.”

If any issues do arise, Shannon states that the buyer’s internal team has to discuss the next best steps and that “in-house counsel should be deliberate in trying to maintain privilege”.

For more information from Shannon on the due diligence process read the full article.

Chip Wry Discusses Planning for Tax Reform in Accounting Today Article 07/05/2017

Posted by Morse Barnes-Brown Pendleton in Attorney News, Financial Services, Taxation.
Tags: , ,
add a comment

M0846619Accounting Today’s article “Getting Ahead of Tax Reform” discusses the importance of planning and action for businesses before the potential tax reform takes place. Tax attorney Chip Wry comments on the uncertainty of which pieces of the proposed legislation will be enacted, and notes the possible implications regarding the elimination of the interest expense deduction and the expensing of capital expenditures. Chip also discusses how tax reform could affect choice of entity for new businesses, particularly the choice between C corporation or LLC. Chip notes:

Before the individual rates went up under the current rules, we formed a higher percentage of companies as LLCs than after they increased… But with the increase in rates, we were more willing to form companies as a C corporation.”

For more of Chip’s insights into potential tax reform, read the full Accounting Today article.

ConforMIS Receives FDA Clearance for iTotal Hip Replacement System 06/27/2017

Posted by Morse Barnes-Brown Pendleton in Client News, Life Sciences, Medical Devices.
Tags: ,
add a comment

conformis-inc-logoFirm client ConforMIS, Inc. received FDA 510(k) clearance for its primary iTotal Hip replacement system. Chief Executive Officer and President Mark Augusti remarked:

Having treated over 50,000 patients with customized knee replacement implants, ConforMIS brings over a decade of experience in patient-specific technology to the hip replacement market. FDA clearance of iTotal Hip demonstrates the ability to apply our proprietary iFit® image-to-implant technology to other joints. There has been a trend towards personalized healthcare and we believe patients expect and deserve personalized treatment.”

The iTotal Hip replacement system has technology that is similar to that used in ConforMIS’s customized knee implants. The company hopes to improve patient outcomes through customized implants for joint replacements.

Congratulations to our client on this achievement. For more information, read the full announcement.

Matal v. Tam: The Supreme Court Rejects the Prohibition on Disparaging Trademarks 06/22/2017

Posted by Morse Barnes-Brown Pendleton in Attorney News, Intellectual Property.
Tags: , , ,
add a comment

Sean D. Detweiler (SDD)By: Sean Detweiler and Bianca Sena

On Monday June 19, 2017, the U.S. Supreme Court ruled that the U.S. Trademark Office’s denial of registration for “disparaging” trademarks under Section 2(a) of the Lanham Act violates the Free Speech Clause of the First Amendment and is therefore unconstitutional. The case, Matal v. Tam (previously known as Lee v. Tam) concerned the federal trademark registration of “The Slants,” an all Asian-American rock band. The Court affirmed the Federal Circuit’s decision that Section 2(a) constituted viewpoint-based discrimination because it necessarily required a subjective value judgment on whether something is “disparaging.” The decision upended a portion of statute that has been in place since 1946. The decision will likely impact a parallel trademark case, Pro Football Inc. (a.k.a., the Redskins case), which involves the same disparagement clause section of the Lanham Act and cancellation of the Redskins trademark registrations.

For further detail, read “Matal v. Tam: The Supreme Court Rejects the Prohibition on Disparaging Trademarks”. For more information on trademarks, please contact Sean Detweiler.

The Risks of Using Finders and Unregistered Brokers 06/21/2017

Posted by Morse Barnes-Brown Pendleton in Attorney News, Corporate, Financial Services, Private Investment Funds & Advisers.
Tags: , , , ,
add a comment

JHW Headshot Photo 2016 (M0990045xB1386)Private fund managers often use placement agents, finders, and other intermediaries to help raise capital for their investment funds. Using an intermediary that has failed to register as a broker-dealer, however, is fraught with risk. In his article “The Risks of Using Finders and Unregistered Brokers”, private funds attorney Josh Watson cautions against using unregistered brokers and describes how to determine when an intermediary should be registered.

Read the full article on our website. For more information, please contact Josh Watson or a member of our PIFA practice.

iSpecimen Unveils Online Biospecimen Marketplace 06/13/2017

Posted by Morse Barnes-Brown Pendleton in Client News, Life Sciences.
Tags: , ,
add a comment

iSpecimen Logo (M0910032xB1386)Firm client iSpecimen has launched an online biospecimen marketplace for the life sciences industry. The company hopes that the marketplace will alleviate scientists’ difficulty in finding high-quality samples of human material necessary to conduct research.

The marketplace compiles available samples and allows users to search by patient information. Users can then order the corresponding materials.

For more information about the iSpecimen Marketplace, read the full article in the BBJ, or iSpecimen’s press release.

Registration Exemptions for Investment Advisers 06/08/2017

Posted by Morse Barnes-Brown Pendleton in Attorney News, Corporate, Financial Services, MBBP news, Private Investment Funds & Advisers, Venture Capital & Private Equity.
Tags: , , , , ,
add a comment

JHW Headshot Photo 2016 (M0990045xB1386)When may an investment adviser avoid registering with the Securities and Exchange Commission? Private funds attorney Josh Watson answers this question in his article “Registration Exemptions for Investment Advisers” that summarizes the requirements of two registration exemptions that are available to managers of private investment funds.

To learn about the two registration exemptions read the full article on our website. For more information, please contact Josh Watson or a member of our PIFA practice.

Chip Wry Discusses Choosing a Business Structure in Inc. Magazine Article 06/07/2017

Posted by Morse Barnes-Brown Pendleton in Attorney News, Taxation.
Tags: , , , ,
add a comment

M0846619Inc. Magazine’s article “10 Questions to Ask Yourself Before Choosing a Business Structure” offers a primer on choosing a company’s business form. Tax attorney Chip Wry notes that “choosing a business entity is like looking into the crystal ball of your company’s future”. The article covers some of the differences between S corp, C corp, B corp and LLC and what those differences can mean for the future of a company.

For more information, please read the full article or contact Chip Wry.

Encore Event! Strategic Alliances: Pot of Gold or Pretty Poison? – Life Sciences Series, June 28 06/05/2017

Posted by Morse Barnes-Brown Pendleton in Attorney News, Corporate, Events, Life Sciences, MBBP news.
Tags: , , , ,
add a comment

JMH Headshot Photo 2015 (M0846571xB1386)Due to overwhelming demand for our April 28 “Strategic Alliances: Pot of Gold or Pretty Poison?” event, we will be holding another round on Wednesday, June 28 at the Cambridge Innovation Center (CIC). Moderated by corporate attorney John Hession, a panel of business development experts will explore various research and collaboration structures, from options to license to comprehensive collaboration partnerships. The panel will discuss various licensing vehicles, the importance of concise fields of use descriptions, sample economics, and conventional transaction structures.

Space is limited! View our event page for more information and to register for the event.

%d bloggers like this: